机构：[1]Department of Vascular Surgery, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China[2]Department of Nephrology, Suzhou Research Center of Medical School, Suzhou Hospital, Affiliated Hospital of Medical School, Nanjing University, Suzhou, China[3]Department of Nephrology, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China[4]Department of Nephrology, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China[5]Department of Vascular Surgery, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China中山大学附属第一医院[6]Department of Nephrology, The First Affiliated Hospital of Dalian Medical University, Dalian, China大连医科大学附属第一医院[7]Department of Nephrology, The Second Affiliated Hospital of Guizhou University of Traditional Chinese Medicine, Guiyang, China[8]Department of Nephrology, Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, Hangzhou, China[9]Department of Vascular Surgery, China-Japan Friendship Hospital, Beijing, China[10]Department of Nephrology, Affiliated Hospital of Jiangsu University, Zhenjiang, China[11]Department of Nephrology, Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China, Chengdu, China四川省人民医院[12]Department of Vascular Surgery, Suzhou Municipal Hospital, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou China[13]Kidney Disease Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China浙江大学医学院附属第一医院[14]Department of Nephrology and Rheumatology, Guangdong Provincial Hospital of Chinese Medicine Hainan Hospital, Haikou, China广东省中医院[15]Department of Nephrology, Mianyang Central Hospital, Mianyang China[16]The National Clinical Research Center of Kidney Diseases, Jinling Hospital, Nanjing University School of Medicine, Nanjing, China[17]Department of Nephrology, Affiliated Cancer Hospital of Guizhou Medical University, Guizhou, China[18]Department of Nephrology, No. 2 People’s Hospital of Fuyang City, Fuyang, China[19]Department of Nephrology, Suzhou Hospital of Integrated Traditional Chinese and Western Medicine, Suzhou, China[20]Kidney Institute, Blood Purification Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China[21]Department of Nephrology, Taizhou Hospital of Zhejiang Province, Taizhou, China台州恩泽医疗中心台州医院[22]Department of Nephrology, People’s Hospital of Suzhou New District, Suzhou, China[23]Department of Nephrology, The Second People’s Hospital, Wuhu, China[24]Department of Nephrology, Anqing Shengtong Nephropathy Hospital, Anqing, China[25]Department of Nephrology, The Second Affiliated Hospital of Anhui Medical University, Hefei, China[26]Department of Nephrology, Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Science), Southern Medical University, Guangzhou, China[27]Department of Nephrology, The First Hospital of Hebei Medical University, Shijiazhuang, China[28]Department of Vascular Surgery, The No.1 Affiliated Hospital of Kunming Medical University, Kunming, China[29]Department of Nephrology, Beijing Haidian Hospital (Haidian Section, Peking University Third Hospital), Beijing, China
The radial artery deviation and reimplantation (RADAR) technique uses an artery-to-vein (end-to-side) configuration. We have developed a modified RADAR (M-RADAR) technique. This new technique enables a side-to-side anastomosis between the vessels, and furthermore, the distal cephalic vein is ligated. The VAC Study (Paradigm Shift in Vascular Access Creation) is a multicenter randomized controlled trial comparing the clinical outcomes of radiocephalic fistula created using the conventional technique (CT group) versus the modified RADAR method (M-RADAR group).Prospective, multicenter, randomized study starting in December 2024. Participant recruitment has commenced. All data are collected via paper-based Case Report Forms (CRFs). The primary clinical endpoints include the 1-year primary patency rate of AVF and the incidence of venous juxta-anastomotic stenosis. Secondary endpoints include the 1-year access-assisted primary patency, access cumulative patency, hospitalization rates, mortality, and an analysis of the economic costs associated with maintaining vascular access. An estimated 408 participants will be recruited from approximately 29 dialysis units across China.A high-quality, adequately powered multicenter randomized controlled trial (RCT) is still needed to provide clear guidance for clinicians on selecting optimal treatment strategies for the cephalic vein during AVF surgery.Registration number: ChiCTR2400093537, Registered on 2024-12-06.
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2025]版：
大类|4 区医学
小类|4 区外周血管病
最新[2025]版：
大类|4 区医学
小类|4 区外周血管病
第一作者：
第一作者机构：[1]Department of Vascular Surgery, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China[2]Department of Nephrology, Suzhou Research Center of Medical School, Suzhou Hospital, Affiliated Hospital of Medical School, Nanjing University, Suzhou, China
共同第一作者：
通讯作者：
推荐引用方式(GB/T 7714)：
Guocun Hou,Lanhua Mi,Fan Bian,et al.Study protocol for paradigm shift in vascular access creation: The VAC study[J].The Journal Of Vascular Access.2025,11297298251321983.doi:10.1177/11297298251321983.
APA：
Guocun Hou,Lanhua Mi,Fan Bian,Dongping Chen,Guangqi Chang...&Yaxue Shi.(2025).Study protocol for paradigm shift in vascular access creation: The VAC study.The Journal Of Vascular Access,,
MLA：
Guocun Hou,et al."Study protocol for paradigm shift in vascular access creation: The VAC study".The Journal Of Vascular Access .(2025):11297298251321983
